Skip to main content
Premium Trial:

Request an Annual Quote

Nucleonics Adds $8.3M to Series B Funding

NEW YORK, June 2 (GenomeWeb News) - Nucleonics has added a second capital infusion to Series B funding first closed in March, the Malvern, Pa.-based RNAi company said yesterday.


New investor Quaker BioVentures of Philadelphia participated in the $8.3 million second close, joining previous investors New Enterprise Associates of Baltimore, and SR One of West Conshohocken, Pa., to bring the round to $49.2 million, following a $40.9 million first close in March.


The 12-employee firm, which, according to RNAi News, GenomeWeb's sister publication, was founded in 2001 to commercialize gene-silencing technology developed by the company's founders while they were scientists at Apollon, is currently developing an RNAi-based treatment for hepatitis B, which is expected to be ready for phase I testing as early as the first quarter next year. The firm's technical approach is to use DNA plasmids that have been designed to express long pieces of double-stranded RNA targeting multiple genomic sequences.


The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.